Startups
MERIT is an innovative, global specialty CRO focusing on ophthalmology and respiratory clinical trial endpoint services. Our portfolio of solutions offers deep clinical expertise, unique technology, and exceptional service for our partners, sponsors, and CROs.
MERIT is the union of two exceptional specialty Contract Research Organizations (CRO): EyeKor in ophthalmology and CompleWare in respiratory. Our ophthalmology team has extensive knowledge and experience in managing and evaluating images, especially with ocular diseases affecting the retina. Our respiratory services include standardized collection and consistent interpretation of spirometry data along with personalized service to ensure accurate, actionable outcomes. Rely on us as a trusted R&D partner.
MERIT is the union of two exceptional specialty Contract Research Organizations (CRO): EyeKor in ophthalmology and CompleWare in respiratory. Our ophthalmology team has extensive knowledge and experience in managing and evaluating images, especially with ocular diseases affecting the retina. Our respiratory services include standardized collection and consistent interpretation of spirometry data along with personalized service to ensure accurate, actionable outcomes. Rely on us as a trusted R&D partner.
Overview
Location
United States, Wisconsin, Madison
Employees
51-200
Founded date
2012
Mentions in press and media 19
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 13, 2026 | MERIT Announces Strategic Collaboration with MTI to Provide Spirometry Endpoints | MERIT, Your Clinical Endpoint Expert For Too Long, Spirometry Had One Way In. Not Anymore. This partnership accelerates the future of respiratory assessment. Together, we’re setting a new benchmark for how spirometry should be captured, rev... |
| Apr 30, 2026 | ARVO 2026 Poster Shows Strong Agreement Between Manual & Semi‑Automated OCT Methods to Identify High‑Risk AMD Lesions | MERIT, Your Clinical Endpoint Expert The ability to reliably identify and localize iRORA lesions is critical for understanding disease progression and for evaluating emerging therapies in Dry AMD.” — Ronald P. Danis, M.D., co-author & C... |
| Mar 30, 2026 | MERIT Announces Successful FDA Inspection | MERIT, Your Clinical Endpoint Expert EXCELSIOR Software by MERIT We are very proud of this result. A no‑483 outcome is a testament to the discipline, expertise, and dedication of our entire team.” — Yijun Huang, CEO of MERITMADISON, WI, UNI... |
| Aug 12, 2025 | MERIT Earns Spot on Inc. 5000 for Eighth Consecutive Year, Celebrating Sustained Growth and Innovation | MERIT, Your Clinical Endpoint Expert Eight years of consistent recognition is validation of our commitment to delivering bench-to-bedside, reliable, collaborative services to our clients through our EXCELSIOR™ platform.” — Yijun Huang, Co-F... |
| Feb 11, 2025 | MERIT Announces Formation of New Subsidiary, MERIT CRO CANADA, INC. | MERIT, Your Clinical Endpoint Expert This strategic expansion underscores MERIT's commitment to enhancing its global footprint & delivering comprehensive clinical & preclinical endpoint services. By establishing a presence in Canada... |
| Jan 22, 2025 | MERIT Acquires OSOD, Expanding Capabilities in Early-Stage Drug Development | MERIT, Your Clinical Endpoint Expert This strategic acquisition enhances MERIT's service offerings, enabling a seamless transition from preclinical to clinical phases of drug development. This acquisition represents a significant milestone ... |
| Aug 13, 2024 | MERIT Celebrates 7th Consecutive INC 5000 Listing | This honor is a direct result of both the hard work of our entire team as well as our commitment to delivering innovation to our clients through our proprietary EXCELSIOR™ technology platform.” — Yijun Huang, Co-Founder and CEO of MERITMADI... |
| Oct 25, 2023 | MERIT and Mianus Capital Announce Formation of Ophthalmology Scientific Advisory Council | MERIT, Your Clinical Endpoint Expert Mianus Capital The SAC will advise MERIT & Mianus on cutting edge technology & treatments to keep the firms aligned with market needs & help drive innovation in life sciences. We are proud to... |
| Apr 21, 2023 | Mianus to Launch New Venture Capital Fund Focusing on Innovation in Ophthalmology | Mianus Capital Our strategic partnership with MERIT gives us a deep understanding and a unique advantage in the ophthalmology, pharma, and biotech ecosystems.” — Steve Yang, MBANEW YORK CITY, NY, UNITED STATES, April 21, 2023/EINPresswire.c... |
Show more
Reviews 0
FAQ about MERIT CRO
When was MERIT CRO founded?
MERIT CRO was founded in 2012.
What has the press written about MERIT CRO?
Parsers VC has collected 19 articles mentioning MERIT CRO, among them “MERIT Announces Strategic Collaboration with MTI to Provide Spirometry Endpoints” (May 13, 2026) and “ARVO 2026 Poster Shows Strong Agreement Between Manual & Semi‑Automated OCT Methods to Identify High‑Risk AMD Lesions” (Apr 30, 2026).
Is MERIT CRO still active?
Yes, MERIT CRO is active; its latest activity on Parsers VC dates from Aug 11, 2026.